GLICLAVAC MV 0.2

GLICLAVAC MV 0.2 is a triple combination oral antidiabetic medicine containing Gliclazide 80 mg, Metformin 500 mg, and Voglibose 0.2 mg, formulated for the effective management of type 2 diabetes mellitus.

• Gliclazide helps the pancreas release insulin.

• Metformin improves insulin sensitivity and reduces glucose production in the liver.

• Voglibose slows carbohydrate absorption in the intestine, preventing post-meal blood sugar spikes.
  Together, they provide comprehensive blood sugar control throughout the day.

Key Benefits:

• Provides effective triple-action blood sugar control.

• Helps manage fasting and post-meal glucose levels.

• Reduces insulin resistance and enhances glucose utilization.

• Suitable for patients with uncontrolled type 2 diabetes on single or dual therapy.